Status:
UNKNOWN
Study for the Early Diagnosis of Parkinson's Disease
Lead Sponsor:
Bio Shai Ltd.
Conditions:
Parkinson's Disease, Idiopathic
Eligibility:
All Genders
40-80 years
Brief Summary
The main objective of the study is to design and validate the blood based PDx gene expression and miRNA assay for the early diagnosis of Parkinson's disease patients. Differential diagnosis includes p...
Detailed Description
In this study, the PDx assay will be designed and validated in order to distinguish between Idiopathic Parkinson's disease (PD) to patients with similar symptoms and healthy controls. The differential...
Eligibility Criteria
Inclusion
- Patient is able and willing to read the informed consent form
- Patient with clinical diagnosis of Idiopathic Parkinson's Disease according to Queen Square Brain Bank Criteria up to one year prior to enrollment in study
- Patient with diagnosis of MSA, PSP, CBD, Lewy Body Dementia, Essential Tremor or Healthy Control
- Men and Women aged 40-80 years
- Willing and able to comply with procurement of blood sample
Exclusion
- Any medical, psychiatric or other conditions which, in the opinion of the investigator, would preclude participation
- Pregnancy
Key Trial Info
Start Date :
November 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
410 Patients enrolled
Trial Details
Trial ID
NCT02283073
Start Date
November 1 2014
End Date
December 1 2019
Last Update
July 10 2018
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Health Care Campus
Haifa, Israel, 31096,
2
Rabin Medical Center
Petach Tikvah, Israel, 4941492
3
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel, 64239
4
Chaim Sheba Medical Center
Tel Litwinsky, Israel, 52621